机译:分子靶向治疗的进展和现状及胃癌耐药性
Hebei Med Univ Grad Sch Shijiazhuang Hebei Peoples R China;
Hebei Med Univ Hosp 4 Dept Surg 3 Jiankang Rd &
12 Shijiazhuang Hebei Peoples R China;
Hebei Med Univ Hosp 4 Dept Surg 3 Jiankang Rd &
12 Shijiazhuang Hebei Peoples R China;
Hebei Med Univ Hosp 4 Dept Surg 3 Jiankang Rd &
12 Shijiazhuang Hebei Peoples R China;
Hebei Med Univ Hosp 4 Dept Surg 3 Jiankang Rd &
12 Shijiazhuang Hebei Peoples R China;
Hebei Med Univ Hosp 4 Dept Pathol Shijiazhuang Hebei Peoples R China;
Hebei Med Univ Hosp 4 Dept Surg 3 Jiankang Rd &
12 Shijiazhuang Hebei Peoples R China;
Gastric cancer; Drug resistance; Molecule-targeted therapy; Chemotherapy; Targeted drugs; Monoclonal antibodies; Small-molecule drugs;
机译:分子靶向治疗的进展和现状及胃癌耐药性
机译:胃癌肝转移的研究现状与进展
机译:胃癌肝转移的研究现状与进展
机译:在韩国晚期胃癌中Xeloda的全身化疗现状
机译:致力于增强癌症的化学疗法:研究康美他汀和其他化学疗法的药物设计,协同作用以及药物靶标的表达和耐药性。
机译:胆固醇合成破坏与分子靶向药物相结合是EGFR突变体非小细胞肺癌的有希望的代谢治疗
机译:胆固醇合成破坏与分子靶向药物相结合,是EGFR突变体非小细胞肺癌的有希望的代谢治疗